High cholesterol linked to greater breast cancer risk

High cholesterol linked to greater breast cancer risk

In a significant discovery, scientists have found a link between high blood cholesterol and breast cancer in a study of more than one million patients over a 14 year time period in Britain.

“Our preliminary study suggests that women with high cholesterol in their blood may be at a greater risk of getting breast cancer,” said Rahul Potluri, founder of the Algorithm for Comorbidities, Associations, Length of stay and Mortality (ACALM) study.

It raises the possibility of preventing breast cancer with statins, which lowers cholesterol, he added. The researchers conducted a retrospective analysis of more than one million patients across Britain between 2000 and 2013.

There were 664,159 women and of these, 22,938 had hyperlipidaemia and 9,312 had breast cancer. Some 530 women with hyperlipidaemia developed breast cancer.

The researchers found that having hyperlipidaemia increased the risk of breast cancer by 1.64 times.

“We found that women with high cholesterol had a significantly greater chance of developing breast cancer. This was an observational study so we can’t conclude that high cholesterol causes breast cancer but the strength of this association warrants further investigation,” Potluri said.

The research was presented on Friday at “Frontiers in CardioVascular Biology (FCVB) 2014” seminar in Barcelona, Spain.

Source: khaleej times


Could a New Blood Test Predict Breast Cancer Risk?

blood test for Breast Cancer

Researchers believe they may have a new way to test a woman’s risk for breast cancer, even if she doesn’t have an inherited genetic mutation.

The test looks not for mutations, but for changes to how DNA functions — in this case, the BRCA1 breast cancer gene.

It’s important because most cases of breast cancer are not caused by inherited DNA mutations. About 40 percent of breast cancer cases can be explained by genetic susceptibility, which leaves most to outside causes such as diet, exercise, smoking and alcohol use.

“Women who carry the signature are at particularly higher risk of developing breast cancer in the future,” said Martin Widschwendter at University College London, who led the study.

The researchers looked for changes made by a process called methylation, which can step up or down a gene’s function.

BRCA1 brakes cell growth, stopping the out-of-control proliferation that turns a healthy cell into a tumor.

Widschwendter and colleagues tested blood from women with and without BRCA1 mutations before they ever developed breast cancer. Both groups had similar changes in the DNA methylation, they report in the journal Genome Research.

“It was able to predict breast cancer risk several years before diagnosis,” Widschwendter said. The changes may be caused by factors that raise breast cancer risk, such as obesity and drinking too much alcohol, he says.

The researchers tested their “signature” in three different groups of women and found it could consistently predict who would develop cancer five to 12 years later.

“I think this is a productive direction,” says Dr. Jeffrey Weitzel, director for clinical cancer genetics at the City of Hope Cancer Center in Duarte, California.

Breast cancer is the most common cancer affecting women. It will be diagnosed in more than 200,000 U.S. women this year and will kill 40,000.

There’s a debate over how best to prevent it and who benefits most from screening. Right now, women get conflicting advice on when to get mammograms — starting at age 40 or age 50, depending on who’s talking. And there’s disagreement over how often women should get one — once a year, every other year or even every three years.

A simple test that could show who’s at the highest risk of the most dangerous types of breast cancer could help women decide. “A test could help us tailor screening and risk reduction for women,” said Weitzel. For instance, recent research suggested that women with the very highest risk should remove their ovaries.

“We know that we can change risk,” Weitzel said.

Women at high risk can also take tamoxifen to reduce that risk and those at the very highest risk can consider having mastectomies to reduce — but not eliminate — the likelihood that they will get breast cancer. “Most of us think the absolute risk should be 50 percent or more before you offer surgical removal,” said Weitzel.

The test is far from ready for prime time. Right now it’s not terribly accurate, says Widschwendter. It was only tried in a few women. And the team tested blood. It might be better to test cervical cells, perhaps as a test alongside the regular Pap smear that many women get, because these cells respond to the same hormones associated with most cases of breast cancer.

Researchers are still working to understand all the underlying causes of breast cancer. Just this month, another team discovered that women with many moles also had a slightly higher-than-usual breast cancer risk.

More than 75 different genes are linked with breast cancer risk. BRCA1 and BRCA2 are the best known.

Source: NBC news


Fertility drugs not tied to long term breast cancer risk

According to long-term study data published in Cancer Epidemiology, Biomarkers & Prevention, women who took fertility treatments were no more likely to develop breast cancer during 30 years of follow-up than those who never used the drugs, as reported in the Chicago Tribune.

Investigators analyzed records for 9892 women in the US who were followed for some 30 years after having been evaluated for infertility between 1965 and 1988.

Approximately 38 percent of the study participants were exposed to the fertility drug clomiphene, while roughly 10 percent were exposed to gonadotropins. In the 30 years of follow-up, 749 breast cancers were diagnosed among the study participants.

Results suggested that women who were exposed to either type of fertility drug were no more likely to develop breast cancer overall, than those who did not take the medicines to stimulate ovulation.

However, a higher risk of breast cancer was noticed among a small subset of women who had been prescribed the highest doses of clomiphene, although researchers said the reasons for this are unclear.

The authors cautioned that further study of women who receive fertility treatments is needed, because many women included in the current study had not yet reached the age range when breast cancer diagnoses are most common.

Source: First Word